FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
This article was originally published in The Pink Sheet Daily
The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.
You may also be interested in...
Luciana Borio is detailed to National Security Council; FDA promotes Denise Hinton to acting chief scientist.
Office of Medical Policy’s leadership gets reshuffled following retirement of the long-time CDER denizen Rachel Sherman.
More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.